Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib and Topotecan in Solid Tumors and Relapsed Ovarian or Primary Peritoneal Cancer
NCT01012817Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2009
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of veliparib in solid tumor, ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by National Cancer Institute. Started Nov 2009; status: active, not recruiting.
02
Drugs
veliparib
03
Conditions
solid tumorovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01012817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01012817.